CureVac (CVAC) has released an update.
CureVac, a leader in mRNA technology, is set to present the Phase 1 clinical data of its CVGBM glioblastoma cancer vaccine at the ESMO 2024 Congress. The study shows promising safety and initial immunogenicity outcomes for the treatment of one of the most aggressive forms of brain cancer. This marks a significant milestone for the company as it advances its mRNA platform in the development of cancer vaccines.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
